<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00789022</url>
  </required_header>
  <id_info>
    <org_study_id>uriel111</org_study_id>
    <nct_id>NCT00789022</nct_id>
  </id_info>
  <brief_title>Glutamatergic Amino Acids and Oxytocin Levels in the Plasma of Patients in First Psychotic Episode (FPE)- Before and After Neuroleptic Treatment</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shalvata Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shalvata Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of our research is to check the levels of D-Serine, Glycine, and other Glutamatergic&#xD;
      amino acids, in patients with First Psychotic Episode (FPE). These patients are in the early&#xD;
      stage of the disease, treated with neuroleptics for short periods of time, and are usually&#xD;
      hospitalized for the first time. The hypothesis of the research is that we will find low&#xD;
      levels of Glycine and D-Serine in these patients. Following an Anti-psychotic treatment we&#xD;
      will expect these levels to return to the norm, and that this correction will be accompanied&#xD;
      by a reduction of positive and negative symptoms.&#xD;
&#xD;
      In addition, we will check the D-Serine and Glycine levels in the plasma of first degree&#xD;
      relatives of the patients and a group of healthy subjects. The results of this study might&#xD;
      support the hypothesis that the Glutamatergic system in involved in the pathology of&#xD;
      Schizophrenia from it's early stages.&#xD;
&#xD;
      In addition, we will check the levels of Oxytocin and Estrogen in the plasma of patients in&#xD;
      FPE. Our hypothesis is that we will find low levels of Estrogen and High levels of Oxytocin&#xD;
      in this group of patients. The results of the study might support the hypothesis that&#xD;
      Estrogen and Oxytocin are involved in the pathology of Schizophrenia from it's early stages.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <primary_completion_date type="Anticipated">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Glycine and D-Serine levels in the plasma.</measure>
    <time_frame>6-8 weeks</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizophreniform</condition>
  <condition>Schizoaffective Disorder</condition>
  <condition>Brief Psychotic Episode</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>40 subjects in a First Psychotic Episode</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>20 First Degree relatives</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>20 Healthy subjects</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients First degree ralatives Healthy subjects from the community&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects between 18-60 years&#xD;
&#xD;
          -  Clinical Diagnosis of Schizophrenia, Schizophreniphorm disorder, Schizoaffective&#xD;
             Disorder, Brief esychotic episode&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  two years or more of positive symptoms&#xD;
&#xD;
          -  Neuroleptic treatment for more then twe weeks in the prior month, or for more then six&#xD;
             weeks at any time.&#xD;
&#xD;
          -  Drug induced psychotic episode&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Uri Nitzan, Md</last_name>
    <phone>00-972-9-7478532</phone>
    <email>urini@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Uriel Levi-Herscho, MD</last_name>
    <phone>00-972-2-5316906</phone>
    <email>uriel heresco-levy [urielh@ekmd.huji.ac.il]</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shalvata Medical Center</name>
      <address>
        <city>Hod Hasharom</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>November 9, 2008</study_first_submitted>
  <study_first_submitted_qc>November 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2008</study_first_posted>
  <last_update_submitted>November 10, 2008</last_update_submitted>
  <last_update_submitted_qc>November 10, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 11, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Uri Nitzan</name_title>
    <organization>Resident</organization>
  </responsible_party>
  <keyword>First-Psychotic-Episode (FPE)</keyword>
  <keyword>Glutamatergic system</keyword>
  <keyword>Glycine</keyword>
  <keyword>D-Serine</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Estrogen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

